CINV

Cantor Fitzgerald’s Chiara Russo mentioned that with Heron Therapeutics Inc (NASDAQ: HRTX)'s lead product, Sustol, coming up for FDA approval, there was potential for a differentiated label that would cover both delayed and acute CINV (Chemotherapy-Induced Nausea and Vomiting). The analyst...